PhaseBio Pharmaceuticals, Inc.

Late-stage studies in non-small cell lung cancer are high risk but potentially high reward bets and Gilead has just found a partner to back its gamble on Trodelvy (sacituzumab govitecan). The biosci

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Takes On XinThera’s Preclinical

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Dragonfly Takes Back IL-12 Immunotherap

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr